[Clinical analysis of eculizumab in the treatment of atypical hemolytic uremic syndrome in children].

Eculizumab can significantly improve renal function, reduce the incidence of renal failure in the treatment of pediatric atypical hemolytic uremic syndrome and is associated with high safety and few adverse reactions. The decision on treatment discontinuation can be made following the physician-patient shared decision-making model, with the timing reasonably chosen based on the patient's clinical condition and family financial status.